Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Zydus receives tentative approval from USFDA for Budesonide delayed release capsules, 4 mg".
Press Release Nov 04 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Budesonide delayed-release capsules. The capsules are indicated for treating mild to moderate active Crohn's disease in adults and children.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Oct 29 2025
- Press Release Oct 24 2025
- Press Release Oct 06 2025
- Press Release Oct 01 2025
- Press Release Sep 23 2025
Later from Zydus Lifesciences
- Press Release Nov 05 2025
- Press Release Nov 06 2025
- Press Release Nov 07 2025
- Zydus Lifesciences Limited Press Release Nov 11 2025
- Press Release Nov 13 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences